J Clin Oncol: Efficacy and safety of Poziotinib in the treatment of advanced NSCLC with HER2 exon 20 mutation

About 3% of lung cancer patients carry human epidermal growth factor receptor 2 (ERBB2, HER2) mutations; in non-small cell lung cancer ( NSCLC ), about 48% of HER2 mutations are exon 20 mutations
.

So far, the needs of targeted therapy for NSCLC patients with HER2 mutations have not been fully met

NSCLC

Poziotinib is an innovative oral broad-spectrum HER inhibitor that can irreversibly block the signal transmission of all HER family tyrosine kinase receptors
.

Preclinical trials have shown that the inhibitory effect of Pozitinib on HER receptors carrying exon 20 insertion mutations is dozens of times higher than that of existing tyrosine kinase inhibitors

Poziotinib is an innovative oral broad-spectrum HER inhibitor that can irreversibly block the signal transmission of all HER family tyrosine kinase receptors.

The recruited advanced NSCLC patients with HER2 exon 20 mutations received Bozitinib 16 mg/day, 28 days as a course of treatment
.

The primary endpoint is the objective response rate

In total, 30 patients received Pozitinib treatment
.

At baseline, 90% of patients had previously received platinum-based chemotherapy, and 53% had received 2-line or higher-line systemic therapy

The best degree of remission for each patient

The best degree of remission for each patient

As of March 1, 2021, the confirmed objective response rate for this study cohort was 27% (95% CI 12-46)
.

Remission was observed in all HER2 exon 20 mutant subtypes

The objective response rate was 27% objective response rate was 27% with a median duration of response was 5.

Duration of remission and progression-free survival

Duration of remission and progression-free survival

The most common grade 3 treatment-related adverse events were skin rash (47%) and diarrhea (20%)
.

One suspected treatment-related death (pneumonia)

Treatment-related adverse events

Treatment-related adverse events

In summary , Pozitinib has shown promising anti-tumor activity in advanced NSCLC patients with HER2 exon 20 mutations, including those who have previously received platinum-based chemotherapy

Pozzi erlotinib in patients with advanced NSCLC carrying HER2 exon 20 mutations, including patients previously treated with platinum-based chemotherapy, showing the anti-tumor activity anticipated pozzi imatinib carrying outer HER2 Among patients with advanced NSCLC with mutations in exon 20, including those who have previously received platinum-based chemotherapy, they have shown promising anti-tumor activity

Original source:

Original source:

Yasir Y.

Poziotinib for Patients With HER2 Exon 20 Mutant Non-Small-Cell Lung Cancer: Results From a Phase II Trial In this message